Navigation Links
UCSF, Sanofi collaborate to find new diabetes cures
Date:1/10/2012

The University of California, San Francisco (UCSF) has signed an alliance with international pharmaceutical company Sanofi (EURONEXT: SAN and NYSE: SNY) to share expertise in diabetes research and identify drug targets that could lead to new therapies for both type 1 and type 2 diabetes.

The $3.1 million collaboration will bring together scientists in three UCSF labs with deep understanding of the biology of beta cells insulin-producing cells that are destroyed in type 1 diabetes and often produce too little insulin in type 2 with Sanofi researchers who are experienced in developing potential drug candidates into actual therapies.

"This is a true partnership between scientists with very different strengths," said Matthias Hebrok, PhD, director of the UCSF Diabetes Center. "UCSF is known for its deep understanding of the underlying biology of diabetes, while Sanofi has great expertise in screening compounds, identifying which molecules have potential, and moving them along to develop a new drug. Such an endeavor is almost impossible to accomplish in a single academic laboratory. Thus, both partners profit from the expertise of the other group."

The alliance is the University's third collaboration with Sanofi, alongside brain trauma and oncology research launched last year, since the two signed a master agreement in January 2011 to work together in translating academic science into potential new therapies. Master agreements lay out the fundamental terms of research collaborations, align with the University's academic mission including broad publication rights, and form part of a core strategy for the UCSF Office of Innovation, Technology and Alliances to expedite that "bench-to-bedside" research.

Partnershp Combines Expertise on Both Sides

This also is the first collaboration of its kind for the UCSF Diabetes Center, extending beyond simpler, funded-research agreements to create a two-way partnership in which scientists on both sides contribute technology and expertise to identify drug targets and test their potential.

"Sanofi is pleased to collaborate with the Diabetes Center at UCSF to combine expertise in employing new technologies for the development of innovative diabetes therapies," said Pierre Chancel, senior vice president in the Diabetes Division at Sanofi. "The potential resulting drug discovery projects will supplement our integrated solutions model for diabetes management and help Sanofi continue to deliver best-in-class solutions to people living with diabetes."

Together, the team will assess and validate potential drug targets from a UCSF library of roughly 100,000 small interference RNAs (siRNA) molecules that play a crucial role in turning on and off genes, including the gene that produces insulin. They also will identify Sanofi compounds that might be effective in regulating those molecules, study the impact those compounds have on UCSF laboratory models of diabetes and assess their therapeutic potential.

In the United States alone, 46 percent of adults had diabetes or pre-diabetes in 2010, according to the U.S. Centers for Disease Control and Prevention (CDC), which projects a full third of Americans will have the disease in 2050. It is the leading cause of blindness and kidney failure, a major cause of heart disease and stroke, and the seventh-highest cause of death in the U.S. Diabetes care costs $116 billion each year in the United States alone, according to the CDC, with an additional $58 billion toll in lost productivity and early mortality.

The initial project, intended as a pilot for broader joint research into diabetes, will operate under the oversight of an expert panel from UCSF and Sanofi, and focus on beta cells, drawing on the expertise of three renowned UCSF Diabetes Center researchers and their laboratories:

Michael McManus, PhD, a molecular biologist and expert in microRNA and the way genes are expressed, or turned into genetic products such as insulin and other proteins; Hebrok, an expert on beta-cell biology and development who holds the UCSF Hurlbut-Johnson Distinguished Professorship in Diabetes Research; and Michael German, MD, an expert on beta-cell function and how cells transcribe DNA into RNA to create proteins, who is clinical director of the Diabetes Center and holds the Justine K. Schreyer Endowed Chair in Diabetes Research.

UCSF and its Diabetes Center have a long history of breakthroughs in diabetes and beta-cell research, spanning from the first cloning of the insulin gene to the first clinical studies blocking autoimmune destruction of beta cells. UCSF Diabetes Center researchers and their affiliated members are renowned experts in their respective fields: immunology, b-cell biology, islet and pancreas transplantation, and RNAi/microRNAs.


'/>"/>
Contact: Kristen Bole
kristen.bole@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related biology news :

1. UCSF, GE Healthcare team up on pioneering cord blood project
2. Dana-Farber and sanofi-aventis establish cancer research alliance
3. Sanofi-aventis enters into a research and development collaboration with UCSF
4. Institut Pasteur Korea and Sanofi open a new research collaboration to combat HBV
5. Entrust, 3M Collaborate to Provide End-to-End Secure ePassport Solution
6. Animal trackers collaborate on new Google Earth for oceans
7. Springer and Senckenberg society to collaborate on life sciences and geosciences journals
8. UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine
9. Imperial College London and NTU collaborate to offer joint Ph.D. programs in engineering and science
10. Springer to collaborate with the Human Genome Organization
11. Rutgers to collaborate in $3.4 million effort to improve prostate cancer identification using MRI
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UCSF, Sanofi collaborate to find new diabetes cures
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... 22, 2016  Amgen (NASDAQ: AMGN ) ... QB3@953 life sciences incubator to accelerate the development ... laboratory space at QB3@953 was created to help high-potential ... for many early stage organizations - access to laboratory ... Amgen launched two "Amgen Golden Ticket" awards, providing each ...
Breaking Biology Technology: